High-flying biotech company Acucela is subleasing Boeing's space at the top of Russell Investments Center in downtown Seattle. It's the latest big splash for Seattle-based Acucela, which is developing treatments for sight-threatening diseases. Earlier this year, it raised $162 million in an initial public offering. Now it's taking over some of the best office space in town. Acucela currently is on the 19th floor of the high rise at 1301 Second Ave.